ReviewEuropean journal of nuclear medicine and molecular imaging2011
Molecular imaging in cancer treatment.
Review in European journal of nuclear medicine and molecular imaging, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed.
- Article
- Hypoxia Imaging in Lung Cancer: A PET-Based Narrative Review for Clinicians and Researchers.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Image quality evaluation for a clinical organ-targeted PET camera.Frontiers in oncology · 2024Article
- Molecular MRI-Based Monitoring of Cancer Immunotherapy Treatment Response.International journal of molecular sciences · 2023Review
- Modular Synthesis of Peptide-Based Single- and Multimodal Targeted Molecular Imaging Agents.ACS applied bio materials · 2021Article
- The Role of VEGF Receptors as Molecular Target in Nuclear Medicine for Cancer Diagnosis and Combination Therapy.Cancers · 2021Review
- Recent Advances in Photosensitizers as Multifunctional Theranostic Agents for Imaging-Guided Photodynamic Therapy of Cancer.Theranostics · 2021Review
- High-Throughput PET/CT Imaging Using a Multiple-Mouse Imaging System.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2020Article
- Radiolabeled Dendrimers for Nuclear Medicine Applications.Molecules (Basel, Switzerland) · 2017Review
- Relationship Between Aerobic Fitness, the Serum IGF-1 Profiles of Healthy Young Adult African American Males, and Growth of Prostate Cancer Cells.American journal of men's health · 2017Article
- An imaging-based computational model for simulating angiogenesis and tumour oxygenation dynamics.Physics in medicine and biology · 2016Article
- Radiolabeled cyclic RGD peptides as radiotracers for tumor imaging.Biophysics reports · 2016Review
- Monitoring Apoptosis of Breast Cancer Xenograft After Paclitaxel Treatment With 99mTc-Labeled Duramycin SPECT/CT.Molecular imaging · 2016Article
- Quantitative Evaluation of Tumor Early Response to a Vascular-Disrupting Agent with Dynamic PET.Molecular imaging and biology · 2015Article
- Factors that affect PERCIST-defined test-retest comparability: an exploration of feasibility in routine clinical practice.Clinical nuclear medicine · 2015Article
- Radiolabeled Cyclic RGD Peptide Bioconjugates as Radiotracers Targeting Multiple Integrins.Bioconjugate chemistry · 2015Review
- Molecular imaging of hypoxia in non-small-cell lung cancer.European journal of nuclear medicine and molecular imaging · 2015Review
- PET imaging of apoptosis in tumor-bearing mice and rabbits after paclitaxel treatment with (18)F(-)Labeled recombinant human His10-annexin V.American journal of nuclear medicine and molecular imaging · 2015Article
- Molecular PET Imaging of Cyclophosphamide Induced Apoptosis with 18F-ML-8.BioMed research international · 2015Article
- Chemoenzymatic strategy for the synthesis of site-specifically labeled immunoconjugates for multimodal PET and optical imaging.Bioconjugate chemistry · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
The success of cancer therapy can be difficult to predict, as its efficacy is often predicated upon characteristics of the cancer, treatment, and individual that are not fully understood or are difficult to ascertain. Monitoring the response of disease to treatment is therefore essential and has traditionally been characterized by changes in tumor volume. However, in many instances, this singular measure is insufficient for predicting treatment effects on patient survival. Molecular imaging allows repeated in vivo measurement of many critical molecular features of neoplasm, such as metabolism, proliferation, angiogenesis, hypoxia, and apoptosis, which can be employed for monitoring therapeutic response. In this review, we examine the current methods for evaluating response to treatment and provide an overview of emerging PET molecular imaging methods that will help guide future cancer therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.